Journal of Clinical Oncology, Vol 22, No 5 (March 1), 2004: pp. 811-819
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.04.109
Prognostic Model of Pulmonary Adenocarcinoma by Expression Profiling of Eight Genes As Determined by Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction
Hideki Endoh,
Shuta Tomida,
Yasushi Yatabe,
Hiroyuki Konishi,
Hirotaka Osada,
Kohei Tajima,
Hiroyuki Kuwano,
Takashi Takahashi,
Tetsuya Mitsudomi
From the Department of Thoracic Surgery, Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital; Division of Molecular Oncology, Aichi Cancer Center Research Institute, Aichi Cancer Center, Nagoya, Japan; and Department of Surgery I, Gunma University, School of Medicine, Maebashi, Japan.
Address reprint requests to Tetsuya Mitsudomi, MD, PhD, Department of Thoracic Surgery, Aichi Cancer Center, Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan; e-mail: mitsudom{at}aichi-cc.jp
PURPOSE: Recently, several expression-profiling experiments have shown that adenocarcinoma can be classified into subgroups that also reflect patient survival. In this study, we examined the expression patterns of 44 genes selected by these studies to test whether their expression patterns were relevant to prognosis in our cohort as well, and to create a prognostic model applicable to clinical practice.
PATIENTS AND METHODS: Expression levels were determined in 85 adenocarcinoma patients by quantitative reverse transcriptase polymerase chain reaction. Cluster analysis was performed, and a prognostic model was created by the proportional hazards model using a stepwise method.
RESULTS: Hierarchical clustering divided the cases into three major groups, and group B, comprising 21 cases, had significantly poor survival (P = .0297). Next, we tried to identify a smaller number of genes of particular predictive value, and eight genes (PTK7, CIT, SCNN1A, PGES, ERO1L, ZWINT, and two ESTs) were selected. We then calculated a risk index that was defined as a linear combination of gene expression values weighted by their estimated regression coefficients. The risk index was a significant independent prognostic factor (P = .0021) by multivariate analysis. Furthermore, the robustness of this model was confirmed using an independent set of 21 patients (P = .0085).
CONCLUSION: By analyzing a reasonably small number of genes, patients with adenocarcinoma could be stratified according to their prognosis. The prognostic model could be applicable to future decisions concerning treatment.
Supported in part by the Aichi Cancer Research Foundation.
Authors disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Skrzypski, E. Jassem, M. Taron, J. J. Sanchez, P. Mendez, W. Rzyman, G. Gulida, D. Raz, D. Jablons, M. Provencio, et al.
Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung
Clin. Cancer Res.,
August 1, 2008;
14(15):
4794 - 4799.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Reed, A. Graham, R. S. Hoda, A. Khoor, E. Garrett-Mayer, M. B. Wallace, and M. Mitas
A simple two-gene prognostic model for adenocarcinoma of the lung
J. Thorac. Cardiovasc. Surg.,
March 1, 2008;
135(3):
627 - 634.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Lau, P. C. Boutros, M. Pintilie, F. H. Blackhall, C.-Q. Zhu, D. Strumpf, M. R. Johnston, G. Darling, S. Keshavjee, T. K. Waddell, et al.
Three-Gene Prognostic Classifier for Early-Stage Non Small-Cell Lung Cancer
J. Clin. Oncol.,
December 10, 2007;
25(35):
5562 - 5569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Seike, N. Yanaihara, E. D. Bowman, K. A. Zanetti, A. Budhu, K. Kumamoto, L. E. Mechanic, S. Matsumoto, J. Yokota, T. Shibata, et al.
Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier
J Natl Cancer Inst,
August 15, 2007;
99(16):
1257 - 1269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-Y. Chen, S.-L. Yu, C.-H. Chen, G.-C. Chang, C.-Y. Chen, A. Yuan, C.-L. Cheng, C.-H. Wang, H.-J. Terng, S.-F. Kao, et al.
A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer
N. Engl. J. Med.,
January 4, 2007;
356(1):
11 - 20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. Hayes, S. Monti, G. Parmigiani, C. B. Gilks, K. Naoki, A. Bhattacharjee, M. A. Socinski, C. Perou, and M. Meyerson
Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts
J. Clin. Oncol.,
November 1, 2006;
24(31):
5079 - 5090.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Espinosa, J.A. F. Vara, A. Redondo, J.J. Sanchez, D. Hardisson, P. Zamora, F. G. Pastrana, P. Cejas, B. Martinez, A. Suarez, et al.
Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study
J. Clin. Oncol.,
October 10, 2005;
23(29):
7278 - 7285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Dubinett, D. Elashoff, and M. Meyerson
Assessing Prognosis in Non-Small-Cell Lung Cancer: Avenues to a More Complete Picture?
J. Clin. Oncol.,
August 15, 2004;
22(16):
3209 - 3211.
[Full Text]
[PDF]
|
 |
|
|